

A1M Pharma appoints Chief Medical Officer

A1M Pharma announces that the company has appointed Tobias Larsson Agervald as its new Chief Medical Officer (CMO). Tobias Larsson Agervald is an associated professor and specialist in internal medicine and nephrology with extensive experience in global research and development of pharmaceuticals in both early and later clinical stages. He will assume the position on December 1, 2018.

As CMO, Tobias Larsson Agervald will be responsible for the overall medical strategy as well as designing, implementing and conducting A1M Pharma's clinical development program.

"We are pleased to welcome Tobias Larsson Agervald to our team. As a specialist in nephrology with experience in managing early and later stages of global clinical development, he will add a lot of value as we are now focusing on starting up and conducting our clinical program for ROSgard™. Tobias is a global Key Opinion Leader in nephrology, and his broad international contacts will become very valuable as we prepare to launch upcoming clinical studies," says A1M Pharma's CEO Tomas Eriksson.

"I am excited to start my assignment at A1M Pharma. The company has developed an interesting candidate drug with strong potential based on solid preclinical research. My experience tells me that there is an extensive medical need in kidney protection – the area that the company is now focusing on," says Tobias Larsson Agervald.

Tobias Larsson Agervald has published around 80 scientific articles in high-quality journals such as New England Journal of Medicine, Lancet Diabetes and Endocrinology, PNAS, Circulation, PLOS genetics, Journal of the American Society for Nephrology and Kidney International. He is the co-founder of the European Renal Association - European Dialysis and Transplantation Association's (ERA-EDTA) endorsed Working Group on Mineral and Bone Disorders in connection with acute renal failure and has had the role of advisor for several global pharmaceutical companies such as AbbVie, Sanofi-Aventis, Genzyme, Shire, Amgen and SOBI. Most recently he held the position as Senior Medical Director at Astellas Pharma Global Clinical Development in the Netherlands.

For more information, please contact:

*Tomas Eriksson, CEO
Telephone: +46 46-286 50 30
Email: te@a1m.se*

About A1M Pharma

Several preclinical studies indicate that A1M Pharma's candidate drug, ROSgard™, based on the endogenous protein Alpha-1-Microglobulin, restores impairments to kidney function by repairing damaged tissue and protecting against oxidative stress. Kidney injury is a condition which often occurs in connection with preeclampsia and often limits the possibilities of using radiation therapies as a treatment for cancer. The company's two indications are kidney protection in connection with Peptide Receptor Radionuclide Therapy (PRRT) — a targeted radiation therapy for cancer — with the aim of allowing increased treatment levels and thus fighting metastatic cancer more effectively as well as treatment of preeclampsia. Every year, over 12 million people are affected by acute kidney injuries that can lead to permanent kidney damage. Preeclampsia affects around 10 million pregnant women worldwide and is responsible for 76,000 maternal and 500,000 infant deaths each year. A1M Pharma has been listed on Nasdaq First North Stockholm since 20 June 2017. A1M Pharma's Certified Adviser at Nasdaq First North is Erik Penser Bank AB, +46 8-463 80 00.

This information is of the type that A1M Pharma AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was provided, through the above contact, for publication on 14 August 2018 at 15:45 CET.